Alectinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Alectinib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
97
Registered trials
160
Result records
17
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Alectinib Hydrochloride can convert its Small molecule drug profile and ALK x RET biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Alectinib Hydrochloride (query alias: alectinib) |
|---|---|
| Modality / target | Small molecule drug; ALK x RET; ALK inhibitors, RET inhibitors |
| Highest global status | Approved |
| Originator | Chugai Pharmaceutical Co., Ltd. |
| Active developers | F. Hoffmann-La Roche Ltd., Roche Korea Co., Ltd., Roche China Holding Ltd. |
The MCP disease footprint includes ALK Positive Solid Tumors, Resectable Lung Non-Small Cell Carcinoma, ALK-positive anaplastic large cell lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-UMIN000061476 | Phase 3 | 一般募集中/Open public recruiting | 112 | 3年無病生存割合 |
| NCT07560410 | Phase 1/2 | Not yet recruiting | 10 | Objective Response Rate (ORR) |
| ChiCTR2600125803 | Not Applicable | Not yet recruiting | 43 | R0 resection rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Clinicopathological characteristics and targeted therapy response in ALK fusion–positive lung squamous cell carcinoma: A multicenter retrospective real-world study.
Not Applicable; n=15; evaluation: Positive. Reported fields: -; ORR = 52.6 % ; ORR = 28.6 %
Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.
Not Applicable; n=839; evaluation: Positive. Reported fields: CtDNA clearance = 2.0 Pts ; CtDNA clearance = 3.0 Pts ; CtDNA clearance = 26.0 Pts
188eP - Skeletal muscle, subcutaneous and intramuscular fat as prognostic biomarkers in TKI-treated fusion-positive NSCLC
Not Applicable; n=17; evaluation: Positive. Reported fields: PFS(T1): HR = 1.11, P-Value = 0.03; HR = 1.02, P-Value = 0.04; PFS(T1): HR = 1.11, P-Value = 0.03; HR = 1.02, P-Value = 0.04; PFS(T1): HR = 1.11, P-Value = 0.03; HR = 1.02, P-Value = 0.04
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Alectinib Hydrochloride addresses ALK Positive Solid Tumors, Resectable Lung Non-Small Cell Carcinoma, ALK-positive anaplastic large cell lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 17 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ALK x RET records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-09 | GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year | NDA/BLA | US$8,524.4M stated total |
| 2026-04-17 | 贝达药业控股子公司Xcovery与美国Eversana公司达成恩沙替尼商业化合作 | Approved | Financial terms not disclosed |
| 2026-04-09 | Xuanzhu Bio-B has reached a licensing and supply agreement with Boston Oncology for Pyrotinib and Dirucoclib. | Approved | US$100.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “ALK mutations and uses thereof”. The milestone feed surfaced a patent-application signal described as “RET gene fusions and uses thereof”. The milestone feed surfaced a patent-application signal described as “Alectinib for the treatment of ALK fusion-positive solid or CNS tumours”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
